{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:40:06Z","timestamp":1764139206600,"version":"3.46.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study analyzed severe cutaneous adverse reactions (SCARs) linked to anti-osteoporosis drugs using FDA Adverse Event Reporting System (FAERS) data and characterized implicated drugs and clinical features through a literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective disproportionality analysis of SCAR reports from FAERS (2004\u20132024) utilized signal detection metrics, including reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). A structured literature search across PubMed, Web of Science, and Scopus gathered case reports of SCARs induced by anti-osteoporosis drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 77,789 SCAR reports, 399 (0.51%) involved anti-osteoporosis drugs, mainly affecting female patients (76.25%) with a median age of 69\u00a0years. Denosumab (24%), alendronate (23.25%), and zoledronic acid (17.13%) were most frequently reported. Significant signals included risedronic acid with erythema multiforme [ROR = 9.06; PRR = 9.03; information component (IC) = 3.17], zoledronic acid with cutaneous vasculitis (ROR = 3.15; PRR = 3.15; IC = 1.65), and alendronic acid with Stevens\u2013Johnson syndrome (SJS) (ROR = 4.03; PRR = 4.02; IC = 2.00). The literature review (33 cases) confirmed a median symptom onset of 22\u00a0days, with treatments often involving corticosteroids and supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-osteoporosis drugs, notably bisphosphonates and strontium ranelate, are rarely linked to SCARs but may cause serious consequences. Increased clinical awareness, pre-treatment risk evaluation, and vigilant monitoring are essential for at-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1707885","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:05Z","timestamp":1764138905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun-Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Dong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100239","DOI":"10.1016\/j.bonr.2019.100239","article-title":"DRESS syndrome in response to denosumab: first documented case report","volume":"12","author":"Al-Attar","year":"2020","journal-title":"Bone Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2147\/CCID.S458750","article-title":"Delayed inflammatory reaction to hyaluronic acid dermal filler following zoledronic acid administration: a case report","volume":"17","author":"Alghamdi","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e929","DOI":"10.4317\/jced.53653","article-title":"Erythema multiforme induced by alendronate sodium in a geriatric patient: a case report and review of the literature","volume":"9","author":"de Arruda","year":"2017","journal-title":"J. Clin. Exp. Dent."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00198-005-1986-1","article-title":"Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England","volume":"16","author":"Barrera","year":"2005","journal-title":"Osteoporos. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1684\/ejd.2024.4699","article-title":"Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate","volume":"34","author":"Barthalon","year":"2024","journal-title":"Eur. J. Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.18176\/jiaci.0709","article-title":"Acute localized exanthematous pustulosis due to alendronate","volume":"32","author":"Bautista-Villanueva","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1398-9995.2008.01836.x","article-title":"Cutaneous vasculitis induced by risedronate","volume":"63","author":"Belhadjali","year":"2008","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/cod.12839","article-title":"Erythema multiforme-like eruption induced by risedronate","volume":"77","author":"Bianchi","year":"2017","journal-title":"Contact Dermat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1468-3083.2008.02856.x","article-title":"Generalized cutaneous drug eruption due to strontium ranelate","volume":"23","author":"Boada","year":"2009","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1187937","DOI":"10.3389\/fmed.2023.1187937","article-title":"Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12020-015-0817-1","article-title":"Eczematous dermatitis due to subcutaneous teriparatide injection","volume":"52","author":"Chu","year":"2016","journal-title":"Endocrine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00018-010-0581-6","article-title":"HLA-G in organ transplantation: towards clinical applications","volume":"68","author":"Deschaseaux","year":"2011","journal-title":"Cell Mol. Life Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00198-015-3384-7","article-title":"A fatal case of DRESS induced by strontium ranelate associated with HHV-7 reactivation","volume":"27","author":"Drago","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","article-title":"The evolving role of disproportionality analysis in pharmacovigilance","volume":"23","author":"Fusaroli","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.18176\/jiaci.0668","article-title":"Erythema multiforme after intake of risedronate: a cross-reactivity study","volume":"31","author":"Garcia-Nunez","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J. Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1440-1797.2009.01125.x","article-title":"Strontium ranelate as a cause of acute renal failure and dress syndrome","volume":"14","author":"Iyer","year":"2009","journal-title":"Nephrol. Carlt."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/j.lpm.2011.07.010","article-title":"Adverse drug reactions of strontium ranelate(Protelos) in France","volume":"40","author":"Jonville-Bera","year":"2011","journal-title":"Presse Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1398-9995.2009.01940.x","article-title":"Strontium ranelate-induced DRESS syndrome: first two case reports","volume":"64","author":"Jonville-B\u00e9ra","year":"2009","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2340\/00015555-1014","article-title":"Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis","volume":"91","author":"Kiny\u00f3","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdcr.2021.02.002","article-title":"Strontium citrate associated drug reaction with eosinophilia and systemic symptoms syndrome with granulomatous dermatitis","volume":"10","author":"Kolitz","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1111\/j.1365-2230.2009.03302.x","article-title":"Bullous DRESS in a patient on strontium ranelate","volume":"34","author":"Kramkimel","year":"2009","journal-title":"Clin. Exp. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2017.12.062","article-title":"Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum","volume":"71","author":"Kranenburg","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00198-008-0677-0","article-title":"Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis","volume":"20","author":"Lee","year":"2009","journal-title":"Osteoporos. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00198-016-3568-9","article-title":"Increased risk of strontium ranelate-related SJS\/TEN is associated with HLA","volume":"27","author":"Lee","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ad.2012.01.023","article-title":"Cutaneous vascular calcifications secondary to treatment with teriparatide","volume":"104","author":"Leis-Dosil","year":"2013","journal-title":"Actas Dermosifiliogr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1117391","DOI":"10.3389\/fphar.2023.1117391","article-title":"Severe cutaneous adverse reactions to drugs: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2023.2251381","article-title":"Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1490334","DOI":"10.3389\/fimmu.2024.1490334","article-title":"Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases","volume":"15","author":"Liang","year":"2024","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"adv40430","DOI":"10.2340\/actadv.v104.40430","article-title":"Denosumab-induced acute generalized exanthematous pustulosis","volume":"104","author":"Marovt","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"B36","first-page":"E22","article-title":"DRESS syndrome with autoimmune hepatitis from strontium ranelate","volume":"97","author":"di Meo","year":"2016","journal-title":"Cutis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.annder.2010.11.006","article-title":"Strontium ranelate-induced DRESS syndrome","volume":"138","author":"Le Merlouette","year":"2011","journal-title":"Ann. Dermatol Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.medcli.2017.05.031","article-title":"Dress syndrome and bilateral panuveitis caused by strontium ranelate","volume":"149","author":"Moreno-Higueras","year":"2017","journal-title":"Med. Clin. Barc."},{"key":"B39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting system (FAERS) database","volume":"25","author":"Morris","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"B40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1759720X10387202","article-title":"Cutaneous side effects of antiosteoporosis treatments","volume":"3","author":"Musette","year":"2011","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s00198-021-06021-2","article-title":"Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report: eruptions cutan\u00e9es diffuses induites par l'administration de l'acide zol\u00e9dronique","volume":"32","author":"Nassar","year":"2021","journal-title":"Osteoporos. Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000519029","article-title":"First report of erythema multiforme minor caused by raloxifene hydrochloride","volume":"13","author":"Norimatsu","year":"2021","journal-title":"Case Rep. Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/bmj.307.6902.484","article-title":"Erythroderma after clodronate treatment","volume":"307","author":"Pajus","year":"1993","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s0091-6749(98)70291-x","article-title":"Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management","volume":"102","author":"Phillips","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/microorganisms11020346","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses","volume":"11","author":"Ramirez","year":"2023","journal-title":"Microorganisms"},{"key":"B46","doi-asserted-by":"publisher","first-page":"05719","DOI":"10.12890\/2025_05719","article-title":"When skin reactions interrupt bone therapy: severe cutaneous adverse reaction to romosozumab leading to treatment discontinuation","volume":"12","author":"Rodriguez Arrieta","year":"2025","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e228336","DOI":"10.1136\/bcr-2018-228336","article-title":"c-ANCA vasculitis after initiation of denosumab","volume":"12","author":"Sanchez","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2438744","article-title":"Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database","author":"Shan","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ageing\/afq026","article-title":"Severe exfoliative dermatitis caused by strontium ranelate: two cases of a new drug reaction","volume":"39","author":"Smith","year":"2010","journal-title":"Age Ageing"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e12984","DOI":"10.1111\/dth.12984","article-title":"Erythema multiforme caused by ibandronate sodium: a rare case report","volume":"32","author":"Song","year":"2019","journal-title":"Dermatol Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e15164","DOI":"10.1111\/dth.15164","article-title":"Zoledronate induced urticarial vasculitis","volume":"34","author":"Swarnkar","year":"2021","journal-title":"Dermatol Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.47102\/annals-acadmedsg.v40n11p510","article-title":"Stevens-johnson syndrome due to strontium ranelate","volume":"40","author":"Tan","year":"2011","journal-title":"Ann. Acad. Med. Singap"},{"key":"B54","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4081\/reumatismo.2013.143","article-title":"Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature","volume":"65","author":"Varenna","year":"2013","journal-title":"Reumatismo"},{"key":"B56","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1684\/ejd.2011.1386","article-title":"Adverse cutaneous drug reactions to ibandronate","volume":"21","author":"Weber","year":"2011","journal-title":"Eur. J. Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/14740338.2023.2147506","article-title":"A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system","volume":"22","author":"Wei","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40360-020-00464-9","article-title":"Common causes and characteristics of adverse drug reactions in older adults: a retrospective study","volume":"21","author":"Woo","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00198-014-2688-3","article-title":"Strontium ranelate related Stevens-Johnson syndrome: a case report","volume":"25","author":"Yang","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"luad085","DOI":"10.1210\/jcemcr\/luad085","article-title":"An unexpected case of cutaneous vasculitis following zoledronic acid infusion","volume":"1","author":"Zahedi","year":"2023","journal-title":"JCEM Case Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1707885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:06Z","timestamp":1764138906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1707885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":61,"alternative-id":["10.3389\/fphar.2025.1707885"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1707885","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1707885"}}